These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9192805)

  • 1. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity.
    Mocikat R; Selmayr M; Thierfelder S; Lindhofer H
    Cancer Res; 1997 Jun; 57(12):2346-9. PubMed ID: 9192805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of xenogenized vaccine cells in vivo.
    Graf N; Adam C; Mocikat R
    Int J Cancer; 2003 Jun; 105(2):217-20. PubMed ID: 12673682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with membrane-associated idiotype provides greater and more prolonged protection of animals from tumor challenge than the soluble form of idiotype.
    Ghosh SK; White LM; Ghosh R; Bankert RB
    J Immunol; 1990 Jul; 145(1):365-70. PubMed ID: 1972719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
    Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
    Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
    Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
    Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
    Savelyeva N; King CA; Vitetta ES; Stevenson FK
    Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with bispecific antibodies.
    Thielemans KM
    Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: preclinical evaluation.
    Wahl U; Nössner E; Kronenberger K; Gangnus R; Pohla H; Staege MS; Kolb HJ; Hallek M; Mocikat R
    Clin Cancer Res; 2003 Sep; 9(11):4240-6. PubMed ID: 14519651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity.
    Selmayr M; Menzel H; Kremer JP; Thierfelder S; Mocikat R
    Cancer Gene Ther; 2000 Mar; 7(3):501-6. PubMed ID: 10766357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
    Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
    Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
    Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
    Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection.
    Syrengelas AD; Levy R
    J Immunol; 1999 Apr; 162(8):4790-5. PubMed ID: 10202021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
    Kwak LW; Campbell M; Levy R
    Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.
    Kaminski MS; Kitamura K; Maloney DG; Levy R
    J Immunol; 1987 Feb; 138(4):1289-96. PubMed ID: 3492546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model.
    Rinaldi M; Fioretti D; Iurescia S; Signori E; Pierimarchi P; Seripa D; Tonon G; Fazio VM
    Biochem Biophys Res Commun; 2008 May; 370(2):279-84. PubMed ID: 18364239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.